The IL-1β and IL-6 levels of 4-ACGC treated groups decreased significantly at the doses of 15 mg/kg (P < 0.01), 30 mg/kg (P < 0.01) and 60 mg/kg (P < 0.05) compared with the CHF group. This evidence concerns the gene IL6 and congestive heart failure.